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As a master regulator that induces B lymphocytes to terminally differentiate into plasma cells 
in humans, the function of Blimp1 protein has been widely investigated. C. elegans is a model 
system in which a better understanding of conserved mechanisms can be obtained with relative 
ease. Hence, in this study, we focused on the regulatory role of BLMP-1, the ortholog of Blimp1 
in C. elegans, to learn more about this important family of proteins and possibly to obtain novel 
insights into Blimp1 function in other organisms. The C. elegans bed-3 gene was reported to 
regulate molting and the vulval precursor cell division pattern, but the mechanism that controls 
the expression of bed-3 was unknown. Previously, researchers found that an NspI fragment in 
the bed-3 gene between intron 2 and exon 5 contained an enhancer activity and our lab further 
localized the enhancer element to a 400bp region named SF2. In a large scale ChIP-Seq study 
done by the modENCODE project, BLMP-1 was found to have a putative binding site in bed-
3 intron 3. Furthermore, our lab found that the expression of a bed-3 reporter was significantly 
down-regulated by a blmp-1 mutation and blmp-1 RNAi. These results raised the possibility 
that BLMP-1 may be the regulator which controls the expression of bed-3 in C. elegans. Here 
we identified the exact BLMP-1 binding sites by in vitro EMSA assays. These sites are located 
within a 200bp SF2-9 region located within bed-3 intron 3, the smallest region we identified 
containing the enhancer activity. In addition, loss of these motifs completely abolished the 
enhancer activity of the SF2-9 region. We also found that disrupting BLMP-1 function caused 
molting defects and vulval cell division pattern abnormality similar to bed-3 mutants, which 
provide additional evidence for BLMP-1 functioning as a transcriptional activator of bed-3. We 
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also identified other chromatin factors that may be involved in bed-3 expression. The role of 
BLMP-1 as a transcriptional activator in C. elegans may help us better understand the 
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Chromatin factors play a very important role in regulating transcription of genes involved 
in many developmental processes. They regulate gene transcription not by directly recruiting 
or blocking recruitment of different RNA polymerases to specific DNA motifs, but indirectly 
through remodeling the structure of the chromatin, thereby activating or silencing gene 
expression (Saha et al., 2006). In detail, chromatin factors modify chromatin structure through 
post-translational modification of specific histone amino acid residues, such as acetylation, 
methylation, phosphorylation and sumoylation (Jenuwein and Allis, 2001). Some chromatin 
factors have been studied intensively in recent years, such as the histone methyltransferase 
(HMT) family and the histone acetyltransferase (HAT) family members (Peterson and Laniel, 
2004). These studies reveal a varied and sometimes unexpected function of some protein 
families. For example, methylation of histone H3 lysine 4 is usually related to gene activation, 
while methylation of histone H3 lysine 9 is related to gene silencing (Gyory et al., 2004; Su et 
al., 2009). Exploring the knowledge of chromatin factors is essential for our understanding of 
gene expression regulation and developmental control. 
 
B-lymphocyte-induced maturation protein-1 (Blimp1), also called PR domain zinc finger 
protein 1 (PRDM1), contains a PR-SET domain near the amino terminus (N-terminus) and five 
C2H2 Zinc finger domains near the carboxyl terminus (C-terminus) which can recognize and 
bind to specific DNA motifs. These two functional domains are connected by a proline-rich 
region. Blimp1 acts as the master regulator of B lymphocytes terminal differentiation into 
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immunoglobulin secreting plasma cells in Homo sapiens (Turner et al., 1994). The ortholog of 
Blimp1 in mice functions with Prmt5 and Prmt7 to help primordial and fetal germ cells escape 
the somatic differentiation cell fate (Ancelin et al., 2006; Eckert et al., 2008). While the ortholog 
of Blimp1 in Xenopus laevis is reported to promote anterior endomesoderm and head 
development (de Souza et al., 1999). Although the SET domain usually functions as a 
methyltransferase, it is thought in Blimp1 the PR-SET domain lacks the catalytic activity 
(Kouzarides 2002; Gyory et al., 2004). In most cases, Blimp1 recruits other chromatin factors 
such as lysine specific demethylase LSD1, histone deacetylase HDAC1/2 and transcriptional 
co-repressor proteins in the Groucho family to form a repressor complex and reduces the 
expression of a gene down-stream (Ren et al., 1999; Yu et al., 2000; Györy et al., 2003; Jennings 
and Horowicz 2008; Su et al., 2009). However, in sea urchins, the Blimp1 ortholog Krox was 
reported to function as a transcriptional activator and repressor simultaneously. Blimp1/Krox 
represses its own expression in mesoderm and probably skeletogenic territories in an auto-
regulation loop, and represses the delta repressor HesC within the nonskeletogenic mesoderm 
directly. In contrast, Blimp1/Krox directly activates both the Wnt8 and Otx genes in a Cis-
regulatory module and induces the transcription of eve and hox11/13b (Davidson et al., 2002b; 
Yuh et al., 2004; Minokawa et al., 2005; Livi and Davidson, 2006; Smith and Davidson, 2008. 
Revised gene network can be seen in the Davidson Lab website: 
http://www.sugp.caltech.edu/endomes/). Recently, a study in zebrafish found that Blimp1 
isoform A directly activates two genes foxd3 and tfap2a for early neural crest development, 
which was the first time that the role of Blimp1 as a transcriptional activator in vertebrates was 
reported. In this study, the researchers found that using dominant activator and repressor 
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mutants, the role of Prdm1a both as a transcriptional activator and a repressor was required for 
migratory NCC (Neural crest cell) development. (Powell et al., 2013). This set of evidence 
suggests that the role of Blimp1 as a master transcriptional activator and repressor in embryonic 
development is evolutionarily conserved, and that Blimp1 may recruit different chromatin 
factors to help it switch between the transcriptional activator and repressor roles in different 
tissues and different developmental stages. 
 
Our lab has been focusing on the development of the C. elegans vulva. C. elegans vulva 
is the hermaphrodite’s egg laying organ and is widely studied to investigate the mechanism of 
organogenesis. The C. elegans vulva develops from six equipotent vulval precursor cells (VPCs) 
named P3.p to P8.p. Among them, P5.p, P6.p and P7.p are induced by EGF and Wnt signaling 
pathways to adopt the vulval cell fate while the other three cells are absorbed by the syncytial 
hyp7 cell. In the fourth larval (L4) stage, P5.p, P6.p and P7.p divide three rounds to form the 
normal vulval structure. Among the three VPCs, P5.p and P7.p each divides three rounds and 
generates seven descendent cells in the mid-L4 stage (Sulston and Horvitz, 1977; Sternberg, 
2006).  
 
The bed-3 gene encodes a protein with a sequence specific DNA binding domain, named 
the BED-type zinc finger domain (Aravind, 2000). The likely human BED-3 ortholog Zinc 
finger BED domain-containing protein 4 (ZBED4) was reported to function as a transcription 
co-activator (BED finger domain) or as a transcription co-repressor (LXXLL motifs) 
(http://www.wormbase.org; Farber et al., 2010). However, the function of BED-3 protein in C. 
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elegans is not well understood. bed-3 was identified in a genetic screen by a mutation which 
disrupts the division of P5.p and P7.p granddaughters, that reduces the descendent cell number 
and shows a severe egg-laying defect (Egl) phenotype (Inoue and Sternberg, 2010). The bed-3 
gene was also identified independently in an RNAi based screen to be involved in molting 
which occurs during the transition from the L4 (fourth larval) stage to the adult stage (Frand et 
al., 2005). Consistent with its role in vulval cell division and molting, bed-3 is mainly expressed 
in vulval cells and the hypodermis. How this expression of bed-3 is regulated is unclear. 
Previously, a 2300bp region named “NspI fragment” located from intron 2 to exon 5 was 
discovered to have the enhancer activity that can drive bed-3 expression in vulval cells and the 
hypodermis (Inoue and Sternberg, 2010). However, which proteins bind to the enhancer 
element to up-regulate bed-3 was still unknown. 
 
The C. elegans Blimp1 ortholog BLMP-1 also contains the PR-SET domain and five 
C2H2 Zinc finger domains (http://www.wormbase.org). Unlike Blimp1, the function of BLMP-
1 in C. elegans has not been investigated. In the modENCODE project, which is short for “The 
National Human Genome Research Institute model organism ENCyclopedia Of DNA Elements” 
and aims to provide the researchers with all of the sequence-based functional elements in the 
model organisms C. elegans and D. melanogaster (Celniker et al., 2009), a genome wide 
analysis of BLMP-1 binding sites using ChIP-seq was conducted and around 7000 putative 
BLMP-1 binding sites across the genome were identified. One of the binding sites was located 
in the intron 3 of bed-3, consistent with the location of the enhancer fragment NspI (Niu et al., 
2011). These results suggested that BLMP-1 may be (at least one of) the protein that binds to 
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the enhancer element of bed-3. 
 
To verify this hypothesis, blmp-1 and other chromatin factors were tested for a role in 
regulation of bed-3. Previously, it was found that mutations or RNAi affecting blmp-1 as well 
as other chromatin factor genes such as lin-53, spr-5, mes-2 and F23D12.5 (for brief description, 
please see Table 1) significantly reduced the expression of GFP in the Pbed-3::gfp strain. 
(Pbed-3::gfp reporter analyzed was generated by inserting the NspI fragment and the bed-3 
promoter upstream of the GFP coding region in a GFP reporter vector. The strain generated by 
injecting the recombinant vector can stably express GFP in vulval cells and the hypodermis 
(Inoue and Sternberg, 2010)). Toward the goal of carrying out in vitro protein/DNA interaction 
assay, previous work had successfully narrowed the NspI enhancer element to a 400bp region 
named SF2 which is located on intron 3 by using a Δpes-10::gfp enhancer assay vector which 
can be activated by insertion of an enhancer element upstream (Hwang and Sternberg, 2004; 
Xie Zhengyang and Jasaon Tan Wei Han, unpublished data). However, the 400bp region was 
still too large to carry out an in vitro assay for protein binding (EMSA- electrophoretic mobility 
shift assay). 
 
In this study, we localized the enhancer element to a minimal 200bp region. The direct 
binding of BLMP-1 Zinc finger domains to the fragment was confirmed by EMSA. Exact 
BLMP-1 binding motifs on the fragment were also identified by EMSA. Mutating the binding 
sites completely abolished the enhancer activity of the 200bp fragment. We also found that a 
blmp-1 null allele tm548 and RNAi against blmp-1 caused phenotypes similar to a partial loss-
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of-function bed-3 allele sy705, including the molting defect and vulval cell division disruption. 
These results demonstrate that BLMP-1 directly binds to the bed-3 intron 3 enhancer and 
positively regulates gene expression. In addition we also identified more chromatin factors 
involved in bed-3 transcription, the orthologs of which in other organisms may interact with 
Blimp1. 
 
Table 1: Chromatin factors that regulate Pbed-3::gfp. 
Candidate gene Human ortholog Function 
F23D12.5   
 
JMJD3 A putative histone H3 di/trimethyllysine-27 
(H3K27me2/me3) demethylase 
(http://www.wormbase.org). 
lin-53 RBBP4 A component of the DRM complex and a 
NuRD-like complex 
(http://www.wormbase.org). 
mes-2 EZH2 A SET domain-containing protein as a member 
of a Polycomb-like chromatin repressive 
complex (http://www.wormbase.org). 
spr-5 LSD1 A H3K4me2 demethylase functioning to 
mediate chromatin remodeling and 
transcriptional regulation 
(http://www.wormbase.org). 
The table was modified from Xie Zhengyang’s thesis. These candidate genes were identified in 




Materials and methods 
C. elegans strains, alleles and transgenic lines 
 Worms were maintained as described (Brenner, 1974). The strains and alleles used in this 
study are shown in Table 2 and Table 3. N2 (standard laboratory wild-type strain) worms, 
mutants and transgenic lines were obtained from the Caenorhabditis Genetics Center 
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(http://www.cbs.umn.edu/CGC/), Mitani lab (http://www.shigen.nig.ac.jp), Sternberg lab 
(Inoue and Sternberg, 2010), or generated previously in the lab by Xie Zhengyang. The 
L4440 plasmid (the RNAi assay control in which no cDNA of interest is inserted into the 
dsRNA expression vector) was obtained from Andrew Fire (http://www.addgene.org/1654/). 
The other RNAi E. coli strains were obtained from a bacteria-feeding library (Open 
Biosystems) (Rual et al., 2004). N2 males and transgenic strain males were generated by heat 
shock following the standard protocol (Sulston and Hodgkin, 1988). 
 
Table 2: Strains and alleles used in this study. 
Strain Genotype Type of mutation* 
 blmp-1(tm548) I Deletion 
 F23D12.5(tm3121) X Insertion/deletion 
BR3147 spr-5(by134) I Missense 
SS186 mes-2(bn11) unc-4(e120)/mnC1 
dpy-10(e128) unc-52(e444) II 
Deletion 
MT8840 lin-53(n833) dpy-5(e61) I Missense 
PD6133 tam-1(cc567) V Nonsense 
MT10430 lin-35(n745) I Nonsense 
ZF1002 unc-119(ed4) III Nonsense 
ZF1249 blmp-1(tm548) I;unc-119(ed4) III - 
*For mutations shown in bold. 
 




 hT2[qIs48] The balancer hT2[qIs48] balances Chromosome I and 
expresses GFP only in the pharynx (myo-2::GFP). 
Homozygotes of hT2 are lethal (McKim et al., 1993). 
 nT1[qIs51] The balancer nT1[qIs51] balances Chromosome V and has 
GFP expression only in the pharynx (sometimes a little 
expression in tail could be observed). Homozygotes of 
nT1 are lethal (Ferguson and Horvitz, 1985). 
NH2447 ayIs2 IV pNH#300(egl-15::gfp) and pMH86. The egl-15 promoter 
is active in adult vm1 vulval muscles. (Mello and Fire, 
1995; Harfe et al., 1998) 
PD4251 ccIs4251 I; 
dpy-20(e1282) 
Integrated array (ccIs4251) contains 3 plasmids: pSAK2, 
pSAK4, and a dpy-20. The myo-3 promoter is active in all 
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IV body-wall and vulval muscles (Mello and Fire, 1995; Fire 
et al., 1998b) 
 
Extrachromosomal array 
C. elegans lacks centromeres, thus injected DNA can be replicated during cell division as 
extrachromosomal arrays, and can be inherited from parents to offspring. As not all injected 
animals produce 100% transgenic progeny, we used a co-injection marker, unc-119(+) (Maduro 
and Pilgrim, 1995). If the Unc (Uncoordinated movement) phenotype of offspring from an 
injected unc-119(-) worm is rescued, it demonstrated that the injection was successful. Because 
the extra-chromosomal DNA transmission efficiency is not 100%, in each generation, we 
needed to select wild-type worms. After two to three generations, the transgenic strains were 
stable, and could be used in further study. 
Microinjection was carried out according to the standard protocol (Described in: Tomas, 




Plasmids for microinjection 
The Δpes-10 enhancer assay was adopted which has been used extensively to study 
enhancers (Hwang and Sternberg, 2004). The vector pPD97.78 contains the Δpes-10 
promoter, which has little or no basal activity but can be activated by if an enhancer is cloned 
nearby. XbaI and SalI restriction sites were designed into the primers for cloning into the 
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plasmid vector pPD97.78. 
Previously, a 400bp fragment named SF2 (Chromosome IV: 9917979..9918378) has 
been found to have the enhancer activity. (All chromosomal coordinates in this thesis are 
given according to WormBase version WS239 unless stated otherwise). To find the minimal 
fragment containing enhancer activity for the EMSA assay, nine sub-fragments (SF2-1 to 
SF2-9) of SF2 were PCR amplified and cloned first into the pCR-Blunt II-TOPO vector 
(Invitorgen). After being sequenced, the XbaI and SalI digested fragments were cloned into 
the pPD97.78 vector. The primers used in this study are listed in Table 4. 
 






Primer Primer sequence 
SF2-1 210 TI0146 GCGCGTCGACTTGAAACATTTGAAAGTTCA 
TI0216 GCGCGTCTAGACCTTTAAGATGAGAATAACT
GG 
SF2-2 211 TI0218 GCGCGTCGACTCTGCTTGGCTAGATGCCA 
TI0219 GCGCGTCTAGAACCAGCTTCTTCGAAAACAT
A 
SF2-3 210 TI0217 GCGCGTCGACTGGTCCAGTTATTCTCATCT 
TI0147 GCGCGTCTAGATTCTTTCAATCCAGTGGCGT 
SF2-4 309 TI0146 GCGCGTCGACTTGAAACATTTGAAAGTTCA 
TI0219 GCGCGTCTAGAACCAGCTTCTTCGAAAACAT
A 
SF2-5 302 TI0218 GCGCGTCGACTCTGCTTGGCTAGATGCCA 
TI0147 GCGCGTCTAGATTCTTTCAATCCAGTGGCGT 
SF2-6 350 TI0146 GCGCGTCGACTTGAAACATTTGAAAGTTCA 
TI0253 CGCGTCTAGACGCGCAATCGTCTACAAAGC 
SF2-7 350 TI0254 GCGCGTCGACTCTGAGATCAAAAGCGGTTAC 
TI0147 GCGCGTCTAGATTCTTTCAATCCAGTGGCGT 
SF2-8 200 TI0254 GCGCGTCGACTCTGAGATCAAAAGCGGTTAC 
TI0256 GCGCGTCTAGA 
GCATTTCTCTTTTCTCAGTTGC 



























































Plasmids for expressing BLMP-1 fusion protein 
blmp-1 cDNA was first generated from total C. elegans RNA using the RevertAid First 
Strand cDNA Synthesis Kit (Thermo Scientific). Then the fragments were PCR amplified 
with the primer pair TI0193 and TI0194 to generate the full length blmp-1 cDNA (2406bp). 
The primer pair TI0200 and TI0194 were used to generate the C-terminal blmp-1 cDNA 
(1440bp). A shorter fragment of BLMP-1 containing the Zn-finger domains (573bp) was 
amplified by the primer pair TI0285 and TI0286. After digesting by XbaI and HindIII, the 
fragments were cloned into the protein expression vector pGEX-KG with a GST (Glutathione 
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S-transferase) tag. We also cloned some of the fragments into the pET-21a vector to produce 
proteins with a His-tag (Polyhistidine-tag). The primer pairs used were: full length cDNA by 
TI0248 and TI0250; C-terminal cDNA by TI0249 and TI0250. These two fragments were 
digested by EcoRI and XhoI and cloned into the pET-21a vector. The cDNA fragment 
containing the conserved Zinc finger domains was amplified by the primer pair TI0287 and 
TI0288. After digesting by NheI and XhoI, the fragment was cloned into the pET-21a vector. 
The primers used in this study are listed in Table 4. 
 
Strain construction 
Construction of transgenic strains with the blmp-1 mutant background 
The transgenic strains (including F1, F2, F3, SF1, SF2, SF3, SF2-1 to SF2-9, mutated SF2, 
mutated SF2-9 strains) were generated in the unc-119(-) background and were selected and 
maintained by the unc-119(+) co-injection marker. To move the array into blmp-1(-) 
background, the blmp-1; unc-119 strain was used. First, the males of the transgenic strains were 
generated by heat shock. Second, the males were crossed with blmp-1; unc-119 hermaphrodites. 
Third, from the second step, L3 (the third larval stage) ~L4 wild-type hermaphrodite offspring 
were selected, the genotype of these worms should be blmp-1/+; unc-119; extra-chromosomal 
array. Fourth, among the progeny, worms with the dumpy phenotype and without the 
uncoordinated phenotype (the phenotype of blmp-1(-)) were chosen. The genotype of these 
worms should be blmp-1; unc-119; extra-chromosomal array (the fraction of this genotype 
among the whole set offspring should be less than 1/4). Because the Unc phenotype of blmp-1; 
unc-119 was rescued, we could conclude that the unc-119(+) co-injection marker was present 
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in these worms, which meant that the whole extra-chromosomal array wss also present. After 
selection of two to three generation for the dumpy and coordinated worms, the constructed 
strains were kept for future analysis. 
 
Constructing lin-35; Pbed-3::gfp and tam-1; Pbed-3::gfp mutants 
lin-35(-) has no obvious phenotype, nor is it X chromosome linked. lin-35 is located in 
chromosome I, and is left of unc-101. The balancer hT2[qIs48] balances Chromosome I and 
expresses GFP only in the pharynx (myo-2::GFP) and was used to construct the lin-35; Pbed-
3::gfp strain. 
First, we let N2 males cross with hT2/M1 (M1 indicates a marker gene), then we picked 
progeny males with GFP expression in the pharynx. Next, we let the males (genotype hT2/+) 
cross with Pbed-3::gfp hermaphrodites. We picked males with GFP expression in the pharynx 
and hypodermis. The males generated in the previous step (genotype hT2/+; Pbed-3::gfp) were 
crossed with lin-35(n745) hermaphrodites, then we picked hermaphrodites with GFP 
expression in the pharynx and hypodermis. The genotype of these hermaphrodites should be 
lin-35/hT2; Pbed-3::gfp. From their offspring, we picked hermaphrodites again without GFP 
expression in the pharynx and with GFP expression in the hypodermis. The genotype of theses 
worms should be lin-35; Pbed-3::gfp (homozygous hT2 is lethal). The constructed strain was 
maintained under the dissecting fluorescence microscope by picking worms with hypodermis 
GFP expression, and was used in further work. 
tam-1(-) also has no obvious phenotype, nor is it X chromosome linked. It is located in 
chromosome V, and is left of unc-76. The balancer nT1[qIs51] balances Chromosome V was 
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used. nT1[qIs51] also has GFP expression only in the pharynx (sometimes a little expression 
in tail could be observed). The procedure was similar to the construction of lin-35; Pbed-3::gfp. 
 
Constructing lin-53(n833) dpy-5(e61); ayIs2 and lin-53(n833) dpy-5(e61); ccIs4251; dpy-
20(e1282) mutants 
First we let N2 males cross to lin-53 dpy-5 hermaphrodites, then the offspring males 
(genotype lin-53 dpy-5/+) were crossed to ayIs2 or ccIs4251; dpy-20. Hermaphrodites with 
GFP expression in sex muscles (ayIs2), or body wall muscles and vulval muscles (ccIs4251; 
dpy-20), were selected. Among these worms, in the cross with ayIs2, 1/2 of the animals should 
have a genotype lin-53 dpy-5/+; ayIs2/+; while in the cross with ccIs4251; dpy-20, 1/2 of the 
animals should have a genotype lin-53 dpy-5/+; ccIs4251/+ (The dpy-20 mutation was not used 
for selection). In the next generation, for each construction, around eight dumpy worms with 
GFP expression were picked and maintained independently on separate plates. Among the 
dumpy worms, in the cross with ayIs2, 1/3 of the animals should have the genotype lin-53 dpy-
5; ayIs2 and 2/3 of the animals should have the genotype lin-53 dpy-5; ayIs2/+. The frequencies 
of the genotypes in the cross with ccIs4251; dpy-20 were similar. Therefore, among the eight 
dumpy worms maintained in separate plates, we could expect that in theory, at least one of the 
eight worms would have the genotype lin-53 dpy-5; ayIs2 or lin-53 dpy-5; ccIs4251, 
respectively. Because the GFP expression intensity in ayIs2 or ccIs4251; dpy-20 homozygous 
is obviously higher than their heterozygous, we could identify worms in the plate with much 
higher GFP expression intensity as having the genotype lin-53 dpy-5; ayIs2 or lin-53 dpy-5; 
ccIs4251. The strains were then maintained and the GFP expression intensity was observed 
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among their offspring. If there was no obvious GFP expression intensity difference between 
parents and offspring, the constructed strain was used in further work. 
However, as the genetic distance between lin-53 and dpy-5 is about 4cM, which means 
that 4% of the gametes from lin-53 dpy-5/+ worms should be recombinant, we needed to verify 
the genotype to ensure the resulting strain was lin-53(n833) homozygous. The derived cleaved 
amplified polymorphic sequences (dCAPS) primers were used here. dCAPS is a technique to 
genotype SNPs or single nucleotide changes in genes (Calderwood et al., 1996). Previously, 
Xie Zhengyang designed the dCAPS primer pair TI0191 and TI0192 (Table 5), and verified 
one of the lin-53 dpy-5 strains. The primer TI0192 was designed with a base pair mismatch to 
introduce the DdeI restriction site if the template contains the lin-53(n833) mutation. First, the 
DNA from N2, lin-53 dpy-5 and the newly constructed lin-53 dpy-5 strains were amplified 
using TI0191 and TI0192. Second, the fragments were digested by DdeI and ran on a 1.5% 
agarose gel. If the fragment contained the lin-53(n833) mutation, it could be digested by DdeI 
and ran faster than the wild-type fragment. Therefore, by looking at whether the fragments 
amplified from the constructed strains ran faster than the wild-type fragment, we could judge 
whether the constructed strains were lin-53(n833) homozygous. Using this approach, we 
verified the genotype of lin-53(n833) in lin-53(n833) dpy-5(e61);ayIs2 and lin-53 (n833) dpy-
5(e61); ccIs4251. 
 








Mutating putative BLMP-1 binding site on SF2 
Putative BLMP-1 binding motif AAAGAGAAA (also named motif D) was mutated to 
CGGCTACGC. First, primer TI0146 and primer TI0252 were used to generate fragment D1. 
Primer TI0251 and primer TI0147 were used to generate fragment D2 (N2 genomic DNA was 
used as the template). Fragment D1 and fragment D2 were designed to have an overlapping 
section containing the mutated putative BLMP-1 binding site. We mixed fragment D1 and D2 
with 1:1 molar ratio, and used the mixture as the template and amplified a longer DNA fragment, 
using TI0146 and TI0147 as the primer pair to generate the targeted mutated SF2 fragment 
(Table 6). This mutated SF2 was cloned into the pPD97.78 vector and injected into unc-119(-) 
worms with unc-119(+) co-injection marker as previously described. 
 
Mutating putative BLMP-1 binding site on SF2-9 
There are six putative BLMP-1 binding motifs in SF2-9, named motifs A, B, C, D, E and 
F. Motifs A and B, motifs E and F are close to each other, therefore motifs A and B, motifs E 
and F were mutated together.  
First, the motif D mutated SF2-9 was generated by the primer pair TI0255 and TI0253 
using D-mutated SF2 as the PCR template. The motif D mutated SF2-9 was used as the template 
for the next fusion PCR. Because motifs A and B are close to the start site of SF2-9, to mutate 
motif A and B, the primer pair TI0295 and TI0253 were used to generate the fragment ABD1 
(TI0295 contains the mutated motifs A and B). Using fragment ABD1 as the template, TI0300 
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and TI0253 were used to amplify the motifs ABD mutated SF2-9 fragment. Motifs CD mutated 
SF2-9 and DEF mutated SF2-9 fragments were also generated in the similar way, using motif 
D mutated SF2 as the PCR template. Primer pairs TI0146+TI0296 and TI0297+TI0147 were 
used to generate fragments CD1 and CD2, respectively. Fragment CD1 and fragment CD2 were 
designed to have an overlapping section which contained the mutated motif C. Then CD1 and 
CD2 were mixed with 1:1 molar ratio as the template, primer pair TI0255 and TI0253 were 
used to amplify CD mutated SF2-9. DEF mutated SF2-9 fragment was amplified with primer 
pairs TI0146+TI0298 and TI0299+TI0147 first, and then was generated with primer pair 
TI0255 and TI0253.  
Second, motifs A and B were mutated together, without motif D mutated. Wild-type SF2 
fragment was used as the PCR template. The PCR was carried out as described above. The 
mutated fragments generated here were all cloned into the pPD97.78 vector as previously 
described. Primers used and sequences mutated are listed in the Table 6 below. 
 
Table 6: Primers for fusion PCR. 
Motif 
mutated 




































Below were motifs mutated in SF2-9 
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Motif D D mutated 
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RNAi assays were carried out according to the standard protocol (Described in: Ahringer, 
2006). cDNA of interest was amplified and cloned into the L4440 vector. Cloned plasmid was 
transformed into E. coli strain with IPTG (Isopropyl β-D-1-thiogalactopyranoside) inducible 
expression of T7 polymerase, HT115 (DE3). After overnight incubation of the E. coli strain in 
liquid culture, NGM (Nematode growth media) plates containing 1mM IPTG were seeded, each 
plate with three small drops of the E. coli suspension. For most of the genes we tested in this 
study, L4/young adult worms were placed on these plates, and worms in suitable stages of the 
next generation were observed. For RNAi agasint unc-37 and hda-1, which cause egg-laying 
deficiency and embryonic lethality, synchronized L1s (the first larval stage worms) were placed 
onto the RNAi plates. When the RNAi-treated L1s grew to targeted stages, they were observed 
under the microscope. 
In this study, we screened chromatin factor orthologs of which interact with Blimp1 in 
humans and other organisms, to test whether they are involved in regulating the expression of 
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Pbed-3::gfp animals. Genes we screened included: blmp-1, hda-1, prmt-7, hda-3, K04F10.1, 
unc-37, T08D10.2, set-9, prmt-5 and set-11. To test whether they regulated Pbed-3::gfp 
expression through the TAM-1/LIN-35-related mechanism, ayIs2 and ccIs4251; dpy-20 worms 
were maintained on RNAi bacteria for tam-1, blmp-1, lin-53, F23D12.5, mes-2 and spr-5. 
 
Observation of bed-3(sy705)-like phenotypes 
Molting defects 
Eggs from N2, bed-3(sy705), lin-53(n833) dpy-5(e61), blmp-1(tm548), spr-5(by134), 
F23D12.5(tm3121), mes-2(bn11) unc-4(e120)/mnC1 dpy-10(e128), tam-1(cc567), lin-35(n745) 
mutants were synchronized by four hour synchronous egg lay, and young adults in the next 
generation were observed under the Nomarski microscope to check whether cuticles were shed 
completely from worm bodies. RNAi treated young adult worms disrupting blmp-1, spr-5, 
F23D12.5, mes-2, tam-1, unc-37 and hda-1 were also observed as described. 
 
Vulval cell count 
Vulval cell numbers were determined in mid-L4 stage worms. Mutant strains and RNAi 
treated worms tested in this study were the same as in “Molting defects”. One problem was that 
in some worms, especially when the worms were not wild-type, the vulval cells were sometimes 
disorganized and it was difficult to count the precise cell number. Thus, there may be small 





For worms with GFP expression related to the enhancer activity, hermaphrodites at the 
mid-L4 stage were mounted on an agar pad on a glass slide and viewed under the 
Nomarski/fluorescence microscope. The animals were examined under the standard 
epifluorescence setting at 1000x and if above-background fluorescence was detectable by eye, 
the animal was scored as having detectable GFP expression. The percentage of animals 
expressing GFP at a detectable level under standard illumination was used as a semi-
quantitative measure of gene expression. In some rare cases, the worms expressed GFP, 
however not in the vulval cells or hypodermal cells. Although the GFP level was detectable, 
these were not counted among fluorescent animals in the enhancer assay.  
For observing ayIs2 and ccIs4251 worms under the Nomarski microscope, because the 
GFP expression in these two strains is very strong, nearly 100% of them had obvious GFP 
expression. Therefore, we counted the number of worms with obviously reduced fluorescence 
intensity under the standard illumination condition. 
 
Fusion protein expression and purification 
Fusion protein expression 
Cloning was described in the “Plasmid construction” part. We inoculated LB with DH5α 
or BL21(DE3) E. coli strain containing the pGEX-KG or pET-21a vector with BLMP-1 cDNA 
on the first day and grew them overnight at 37°C with shaking. The next day, we prepared two 
tubes each containing 3.6mL fresh LB+carbenicillin solution, and added 400μL of the overnight 
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culture to each tube, and shook them at 37°C for one hour until the bacteria went to the Log 
growth stage. Then we added IPTG into one of the two tubes with the final concentration of 
IPTG at 1mM, and shook them at 37°C for another 5-7 hours. Next, the bacteria solution was 
centrifuged. We collected the pellets, re-suspended them in the cold 1x PBS (Phosphate 
buffered saline). The suspension was sonicated, until the bacteria solution became transparent. 
After that, we centrifuged the sonicated solution, discarded the pellets and kept the supernatant. 
The supernatant was verified by running pre-made SDS-PAGE gel and staining with Coomassie 
Brilliant Blue to check whether there was any soluble fusion protein with the right size in the 
supernatant. In this study, we did not find soluble BLMP-1 full length or larger C-terminal 
fusion protein with the right size using pGEX-KG or pET-21a. However, the soluble BLMP-1 
conserved Zinc finger domains fusion protein in pGEX-KG was expressed successfully with 
the right size.  
 
Fusion protein purification 
The soluble fusion protein had a GST tag, which can be bound by Glutathione-Agarose 
beads. First we let the beads swell in water in 4°C overnight. Second, we discarded the 
supernatant and washed the beads once with 1x cold PBS. Then we discarded the PBS and left 
some volume of the PBS to make 50% of bead slurry. Next, we added the 50% slurry into the 
fusion protein supernatant (the volume ratio of the slurry and the fusion protein solution was 
about 1:10). They were mixed gently for 2-3 hours in the cold room rollers (about 4°C). The 
beads were then spun at 500g in 4°C centrifuge for 5 minutes. We discarded the supernatant, 
and washed the beads 3 times with 1x cold PBS. After this step, the beads were bound to the 
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GST tagged fusion protein and could be verified by running a SDS-PAGE gel. The glutathione 
elution buffer (EB) was used to elute the protein (50mM Tris-HCl+10mM Reduced Glutathione, 
pH8.0). We mixed the EB with the beads gently, incubated them at room temperature for 10-30 
minutes with gentle shaking. The beads were precipitated by spinning down at 500g for 5 
minutes. The supernatant was collected which contained the purified fusion protein. The 
purified fusion protein solution was stored in -80°C fridge until use. 
 
EMSA 
The LightShift Chemiluminescent EMSA Kit made by Thermo SCIENTIFIC was used in 
this study. The Instruction book (Number 20148) in the kit was followed except some steps 
were optimized (http://www.piercenet.com/instructions/2160919.pdf). A Bio-Rad ChemiDoc MP 
Imaging System was used to detect the presence of the labeled DNA. The biotin end-labeled 
DNA and competitor DNA fragments were listed below (Table 7). The length of the fragment 
BBF1 (BLMP-1 Binding Fragment 1) was 100bp and it was generated by PCR using the primer 
pair TI0279B and TI0256, while the other fragments were generated directly from annealing 
the oligonucleotides shown in Table 7. 
 
Table 7: Primers and oligonucleotides used for EMSA assay. 











































































The Fisher’s exact test used in this study was performed with the GraphPad Software 
online tool (webpage: http://www.graphpad.com/quickcalcs/contingency1.cfm). Unless noted 
otherwise, the P-value was calculated with two-tailed tests. The significance symbols used in 
this study are: “N”-not significant; “*”-P-value<0.05; “**”-P-value<0.005; “***”-P-




The position weight matrix (PWM) is calculated from the position frequency matrices 
(PFM). It is widely used to find new possible binding sites based on a set of already known 
binding sites which are bound by similar proteins, and this method can distinguish true new 
binding sites from the sites with non-functionally similar sequences. We used the WormBase 
GBrowser "Annotate Sequence Motif" feature to identify motifs similar to known Blimp1 
binding sites. 
For more detailed information, please refer to the webpage 
(http://gmod.org/wiki/MotifFinder.pm) written by Xiaoqi Shi. 
 
Image processing 
Images were processed by the software including Windows Office Suite 2013, Windows 




BLMP-1 activates endogenous bed-3 transcription 
BLMP-1 does not regulate Pbed-3::gfp expression through the TAM-1/LIN-35-related 
mechanism 
In our lab’s previous study, blmp-1 mutation and blmp-1 RNAi were found to down-
regulate Pbed-3::gfp expression (Xie Zhengyang and Jason Tan Wei Han, unpublished data). 
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However, Hsieh et al. discovered that some chromatin factors, such as the class B synMuv 
family genes including tam-1 and lin-35, were required for efficient expression of repetitive 
extra-chromosomal arrays (Hsieh et al., 1999). Mutating tam-1 or lin-35 would lead to 
significantly reduced expression from repetitive extra-chromosomal transgenes. We needed to 
test the possibility that blmp-1(-) may also reduce the expression of Pbed-3::gfp, which is also 
a transgenic line with repetitive extra-chromosomal array, through this mechanism, not because 
the transcription of endogenous bed-3 needs the regulation of BLMP-1. 
To test this possibility, first, we constructed tam-1(cc567); Pbed-3::gfp and lin-35(n745); 
Pbed-3::gfp mutants. We found that tam-1(-) and lin-35(-) significantly reduced the expression 
of Pbed-3::gfp in vulval and hypodermal cells. In vulval cells, the percentage of animals with 
detectable GFP expression was reduced from 48% in Pbed-3::gfp to 11% in tam-1; Pbed-3::gfp 
and 17% in lin-35; Pbed-3::gfp. While in the hypodermis, the percentage of animals with 
detectable GFP expression was reduced from 90% in Pbed-3::gfp to 38% in tam-1; Pbed-3::gfp 
and 48% in lin-35; Pbed-3::gfp (Figure 1A and 1B). The result was consistent with the function 
of TAM-1 and LIN-35 on repetitive transgenes reported before.  
According to Hsieh et al., they did not test whether tam-1 and lin-35 RNAi had the same 
effect on repetitive transgenes as tam-1 and lin-35 mutants. Hence we did a tam-1 RNAi 
experiment (we did not have the lin-35 RNAi bacterial strain) on ayIs2 and ccIs4251; dpy-20, 
the two repetitive integrated transgenes which were reported to be repressed by lin-35 and tam-
1 mutants (Hsieh et al., 2011). tam-1 RNAi repressed the expression of these two transgenes. 
Thus, if disruption of chromatin factors identified in previous studies reduced expression of 
Pbed-3::gfp through the TAM-1/LIN-35-related mechanism, then one could expect RNAi 
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against these chromatin factors on ayIs2 and ccIs4251; dpy-20 animals would give the similar 
result as tam-1 RNAi. However, in addition to blmp-1 RNAi, RNAi against F23D12.5, spr-5 
and mes-2 did not obviously reduce the expression of ayIs2 and ccIs4251; dpy-20, indicating 
that disruption of blmp-1 and the other three genes did not reduce the expression of Pbed-3::gfp 
through the TAM-1/LIN-35-related mechanism. Instead, these four genes may directly up-
regulate endogenous bed-3 expression (Figure 1C). 
In contrast to blmp-1 and the other three genes, RNAi against lin-53 gave conflicting data 
between ayIs2 and ccIs4251; dpy-20 (data not shown). To rigorously test the role of lin-53 in 
transgene expression, lin-53 dpy-5; ayIs2 and lin-53 dpy-5; ccIs4251; dpy-20 strains were 
constructed. Intriguingly, lin-53 mutation efficiently reduced the expression of ayIs2 and 
ccIs4251; dpy-20. Although the reduction by lin-53(n833) was less than the reduction caused 
by tam-1 RNAi, considering that other genes disrupted by RNAi only reduced the expression 
of ayIs2 and ccIs4251; dpy-20 by 0-3% while lin-53(n833) reduced the expression of these two 
strains by 50% and 33%, respectively (Figure 1C), the lin-53 gene can be regarded as an 
efficient activator for repetitive transgene expression. Given that lin-53 is a member of the 
synMuv B family member as are tam-1 and lin-35, we conclude that lin-53(-) down-regulates 
Pbed-3::gfp expression through the TAM-1/LIN-35-related mechanism. Therefore, lin-53 











Figure 1: BLMP-1 does not down-regulate Pbed-3::gfp through the TAM-1/LIN-35-related 
mechanism. The Fisher’s exact test was used here.  
A: Expression of Pbed-3::gfp is obviously reduced by tam-1(cc567) and lin-35(n745) mutants. 
The Y axis shows the percentage of animals with detectable GFP expression in vulval and 
hypodermal cells. The significance between Pbed-3::gfp and the two mutant strains are 
indicated. 
B: Microscope view of Pbed-3::gfp expression reduced by tam-1 and lin-35 mutants. I, II, III, 
view of worms under Nomarski microscope without fluorescence. I’, II’, III’, view of the same 
animals under Nomarski microscope with fluorescence. Animals without GFP expression are 
hard to distinguish from the background. 
C: BLMP-1 and other chromatin factors seem not to regulate the expression of Pbed-3::gfp 
through the TAM-1/LIN-35-related mechanism, except LIN-53. The observation was repeated 
twice with consistent results. Only one set of data was adopted to generate the figure. The Y 
axis shows the percentage of worms with obviously reduced GFP expression (not as strong as 
ayIs2 or ccIs4251; dpy-20). ayIs2: ayIs2 animals with reduced GFP expression by RNAi-
treatment or mutation listed in the bottom. ccIs4251: ccIs4251; dpy-20 animals with reduced 
GFP expression by RNAi-treatment or mutation listed in the bottom. The significance between 
data of L4440 RNAi and other RNAi disrupted genes on ayIs2 and ccIs4251; dpy-20 was 
calculated. Data for lin-53 dpy-5; ayIs2 and lin-53 dpy-5; ccIs4251; dpy-20 were also compared 
to L4440 RNAi data, since the lin-53 RNAi results were conflicting. blmp-1, mes-2, F23D12.5 
and spr5 RNAi treatment data do not have significant difference compared to L4440 RNAi and 
they are not marked with the significance symbols. 
 
Further characterization of the bed-3 intron 3 enhancer element 
Previously, it was found that the NspI fragment (Chromosome IV: 9917779..9919813) 
contained the enhancer element of the bed-3 gene (Inoue and Sternberg, 2010), and a putative 
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BLMP-1 binding site was located in intron 3 (Niu et al., 2011). Further localization was needed 
to confirm that the binding site and the enhancer element were the same. To further localize the 
enhancer element, in vivo enhancer assays were used. The in vivo assay was carried out by 
testing the enhancer activity of sub-fragments of the NspI fragment in inducing the expression 
of the Δpes-10::gfp vector. Previously it was known that the F1 fragment (Chromosome IV: 
9917067..9919356), F2 fragment (sub-fragment of F1, Chromosome IV: 9917067..9918581) 
and the SF2 fragment (sub-fragments of F2, Chromosome IV: 9917979..9918378) had the 
enhancer activity (Xie Zhengyang and Takao Inoue, unpublished data). Although not exactly 
the same, F2 and the NspI fragment partially overlap, and SF2 is entirely within the NspI 
fragment. The SF2 fragment is located in the bed-3 intron 3, consistent with the location of the 
putative BLMP-1 binding site identified before (Figure 2A). 
To further localize the enhancer element within the SF2 fragment, we cloned nine different 
sub-fragments of SF2, named SF2-1 to SF2-9, and assayed their enhancer activity by inserting 
these fragments upstream of the Δpes-10::gfp reporter. We found that sub-fragments SF2-4, 
SF2-5, SF2-6, SF2-7 and SF2-9 had the enhancer activity, since there was detectable GFP 
expression in the hypodermis and vulval cells of transgenic strains carrying these five fragments. 
In contrast, sub-fragments SF2-1, SF2-2, SF2-3 and SF2-8 did not have the enhancer activity 
and could not induce the expression of the Δpes-10::gfp reporter. SF2-9 was the smallest 
fragment (200bp) we found in SF2 to have the enhancer activity (Table 8 and Figure 2B). 
Next, we tried to find which regions of the SF2 fragment were important or required to 
keep the enhancer activity. To identify the critical regions, we compared three groups of sub-
fragments. First, we compared the enhancer activity of SF2-1, SF2-2 and SF2-4. SF2-4 overlaps 
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both SF2-1 and SF2-2. SF2-4 has the enhancer activity, while SF2-1 and SF2-2 do not. 
Comparing the location of SF2-1 and SF2-4, SF2-1 lacks a region: Chromosome IV: 
9918189..9918287. Comparing the location of SF2-2 and SF2-4, SF2-2 lacks a region: 
Chromosome IV: 9917979..9918076. It seems that these two missing regions are important for 
the enhancer activity of SF2-4. The region IV: 9917979..9918076 is named Important Region 
1 (IR1), and the region IV: 9918189..9918287 is named Important Region 4 (IR4). Second, we 
compared the enhancer activity of SF2-3, SF2-5 and SF2-9. Both SF2-3 and SF2-9 are 
overlapped by SF2-5. SF2-5 and SF2-9 has the enhancer activity while SF2-3 does not. SF2-9 
has a region Chromosome IV: 9918129..9918168 that SF2-3 does not include. Although SF2-3 
has a region that SF2-9 does not include, the region seems not to affect the enhancer activity. 
We conclude that the region IV: 9918129..9918168 as another important region (IR2). Third, 
we compared the enhancer activity of SF2-2, SF2-5 and SF2-9. By the same logic used as in 
the second group, we conclude that the region IV: 9918288..9918328 as the fourth important 
region (IR3). 
No all four IRs are required for obtaining the enhancer activity, however. The enhancer 
activity of SF2-4 requires the full length IR1 and IR4. IR2 is present in all the sub-fragments 
which contain the enhancer activity. While IR3 appears to be required for the enhancer activity 
of most of the sub-fragments, SF2-4 is the exception (Figure 2B). It could be speculated that 
the enhancer activity in SF2-4 is different from the others. 
 
Table 8: Sub-fragments of SF2 driving Δpes-10::gfp expression. 
Transgenic strain* % animals with detectable GFP expression (n) 
  Vulva P-valuea Hypodermis P-valuea 
SF2 line 1 39-1-0b 21(97) <0.0001 93(97) <0.0001 
SF2 line 2 39-2-0b 13(71) 0.0001 82(71) <0.0001 
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SF3 line 2 40-1-4b 0(114) - 1(114) - 
SF2-1 line 1 SF2-1-1 2(126) 0.4992 0(126) 0.475 
SF2-1 line 2 SF2-1-2 3(147) 0.1341 0(147) 0.4368 
SF2-2 line 1 SF2-2-1 0(120) 1 2(120) 1 
SF2-2 line 2 SF2-2-2 0(129) 1 1(129) 1 
SF2-2 line 3 SF2-2-3 0(100) 1 2(100) 0.6001 
SF2-2 line 4 SF2-2-5 0(170) 1 5(170) 0.09 
SF2-3 line 1 SF2-3-1 0(119) 1 0(119) 0.4893 
SF2-3 line 2 SF2-3-2 0(142) 1 0(142) 0.4453 
SF2-3 line 3 SF2-3-3 1(154) 1 0(154) 0.4254 
SF2-4 line 1 SF2-4-1 16(92) <0.0001 29(92) <0.0001 
SF2-4 line 2 SF2-4-2 14(121) <0.0001 26(121) <0.0001 
SF2-5 line 1 SF2-5-2 7(76) 0.0094 21(76) <0.0001 
SF2-5 line 2 SF2-5-3 4(97) 0.0432 20(97) <0.0001 
SF2-6 line 1 SF2-6-1 17(151) <0.0001 51(151) <0.0001 
SF2-6 line 2 SF2-6-3 60(101) <0.0001 90(101) <0.0001 
SF2-6 line 3 SF2-6-4 17(161) <0.0001 56(161) <0.0001 
SF2-7 line 1 SF2-7-1 15(143) <0.0001 56(143) <0.0001 
SF2-7 line 2 SF2-7-2 13(167) <0.0001 30(167) <0.0001 
SF2-8 line 1 SF2-8-1 0(137) 1 0(137) 0.4542 
SF2-8 line 2 SF2-8-2 0(119) 1 0(119) 0.4893 
SF2-9 line 1 SF2-9-3 5(137) 0.017 15(137) <0.0001 
SF2-9 line 2 SF2-9-6 5(110) 0.0272 11(110) 0.0012 
Worms were scored at the mid-L4 stage for GFP expression in both hypodermal and vulval 
cells. n represents the total number of mid-L4 worms scored for each strain. % of worms with 
detectable GFP in vulval or hypodermal cells is shown. 
a Compared to 40-1-4 strain using the Fisher’s exact test. 
b These three strains were obtained from Dr. Inoue’s previous students. 39-1-0 and 39-2-0 are 
descended from different injected parents (generated independently). 40-1-4 strain contains a 
sub-fragment of the NspI enhancer region called SF3 which cannot induce GFP expression of 
pPD97.78. 
*Different lines with the same fragment are descended from different injected parents 






Figure 2: Location and enhancer activity analysis of NspI and its sub-fragments. 
The enhancer activity is shown to the left. “+” means that the fragment could induce detectable 
GFP expression of Δpes-10::gfp in vulval and hypodermal cells, and thus has the enhancer 
activity. “-” means that the fragment could not induce detectable GFP expression of Δpes-
10::gfp in vulval and hypodermal cells, and thus does not have the enhancer activity. Rectangles 
in different colors represent different regions of the fragments (NspI fragment in blue color. F1, 
F2 and F3 in green color. SF1, SF2 and SF3 in cyan color. SF2-1~SF2-9 in yellow color. IR1, 
IR2, IR3 and IR4 in pink color). The exact location of each fragment is noted beside the 
fragments. The location of bed-3 is presented in the bottom of both A and B and rectangles 
represent the exons, while the lines between the exons represent the introns. The ruler on the 
top indicates the genomic region of the fragments. 
A: Location and enhancer activity analysis of NspI, F1, F2, F3 and sub-fragments of F2 
(including SF1, SF2 and SF3). F1, F2 and SF1 have extra region compared to NspI, while F3, 
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SF2, SF3 are entirely overlapped by NspI. Therefore the sub-fragments of SF2 are still in the 
NspI fragment. 
B: Location and enhancer activity analysis of SF2-1~SF2-9, and possible important regions IR1, 
IR2, IR3 and IR4. SF2 is in the bottom and is obviously located in bed-3 intron 3. 
 
The enhancer activity of SF2-9 needs specific putative BLMP-1 binding motifs 
The fact that SF2-9 had the enhancer activity suggested that chromatin factors, such as 
BLMP-1, would bind to one or several motifs on SF2-9 to up-regulate the expression of the 
endogenous bed-3 gene. Previous study has found mammalian Blimp1 binding motifs (Lin et 
al., 2002). Based on the Blimp1 binding motifs on four murine genes: c-myc, CIITA, IFNβ and 
Pax-5 (Table 9), we generated a PFM of BLMP-1 in C. elegans, with slight modification. With 
the motif identification tool on http://www.wormbase.org, several putative BLMP-1 binding 
sites were found on SF2-9. They are motif A: AAAGGGAGA (Score: 0.84), B: GGAGGGAAA 
(Score: 0.80), C: ATTCTCATC (Score: 0.75), D: AAAGAGAAA (Score: 0.92), E: 
GAAGAAAAA (Score: 0.79) and F: AATCTCTTT (Score: 0.80) (Figure 3). To identify 
whether these putative binding sites were required for the enhancer activity of the SF2-9 
fragment, the motifs were mutated, and the motif mutated SF2-9 fragment was tested in in vivo 
enhancer assays. 
Because motif D had the highest score, it was tested first. Motif D was mutated to 
CGGCTACGC. The motif D mutation did not affect the enhancer activity of SF2 and SF2-9 
(Table 10 and Table 11). This indicates that motif D is not required for SF2-9 enhancer activity. 
Next, we asked whether motif D would work with other binding motifs to confer the enhancer 
activity of SF2-9. Motifs A and B, E and F are close to each other, therefore they were mutated 
together, within the motif D mutated SF2-9 background (see Materials and Methods). We found 
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that mutating motifs A and B in motif D mutated SF2-9 background completely abolished the 
enhancer activity of SF2-9. Mutating motif C or motifs E and F in motif D mutated SF2-9 
background could not abolish the enhancer activity of SF2-9, although the enhancer activity of 
motifs DEF mutated SF2-9 was reduced significantly compared to wild-type SF2-9 (Table 11). 
These results indicate that motifs A and B are required for the enhancer activity of SF2-9. 
However, is motif D required for the enhancer activity? To explore this problem, we cloned 
motifs A and B mutated SF2-9 (without the motif D mutation) into the Δpes-10::gfp vector. We 
found that only mutating motifs A and B completely eliminated the enhancer activity of SF2-9. 
Therefore, we conclude that motifs A and B are necessary for the enhancer activity of SF2-9. 
Furthermore, we find that the location of motif A (IV: 9918137..9918145) and motif B (IV: 
9918155..9918163) is overlapped by the IR2 (IV: 9918129..9918168), which is present in all 
the sub-fragments of SF2 to have the enhancer activity (Figure 2B and Figure 3). Hence motifs 
A and B may be the two critical binding motifs for BLMP-1 to bind to and to up-regulate the 
bed-3 gene expression. Here we only showed the necessity for motifs A and B for the enhancer 
activity of SF2, but not sufficiency. In future work, we may insert single or multiple copies of 
motifs A and B into the Δpes-10::gfp vector to determine if motifs A and B are sufficient for 
the enhancer activity of SF2. 
 
Table 9: Blimp1 binding sites in murine genes. 
Gene Blimp1 binding site sequence (5’→3’) 
c-myc A A A G G G A A A G 
CIITA G A A G T G A A A T 
IFN-β G A A G T G A A A G 
Pax-5 A A A G T G A A T C 
Four murine genes bound by Blimp1 with the binding motif sequences are listed in the table 
(Lin et al., 2002). Each of the binding motifs contains 10 bases and is with a 5’→3’ direction 
from left to right. When we generated the PFM of BLMP-1 in C. elegans, the tenth base of each 
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binding motif was not taken into account. 
 
Table 10: Enhancer activity analysis of motif D mutated SF2. 
Transgenic strain* % animals with detectable GFP expression (n) 
  Vulva P-valuea Hypodermis P-valuea 
SF2 line 1 39-1-0 21(97) <0.0001 93(97) <0.0001 
SF2 line 2 39-2-0 13(71) 0.0001 82(71) <0.0001 
SF3 line 2 40-1-4 0(114) - 1(114) - 
D mutated SF2 line 1 D_SF2-1 20(135) <0.0001 38(135) <0.0001 
D mutated SF2 line 2 D_SF2-2 34(124) <0.0001 65(124) <0.0001 
D mutated SF2 line 3 D_SF2-3 23(133) <0.0001 44(133) <0.0001 
D mutated SF2 line 4 D_SF2-4 52(133) <0.0001 80(133) <0.0001 
The scoring was done in the same way as in Table 8. 
a Compared to 40-1-4 strain using the Fisher’s exact test. 
* Different lines with the same fragment are descended from different injected parents 
(generated independently) and may differ from each other. 
 
Table 11: Enhancer activity analysis of putative BLMP-1 binding motif mutated SF2-9. 
Transgenic strain % animals with detectable GFP expression (n) 
  Vulva P-valuea Hypodermis P-valuea 
SF3 line 2 40-1-4 0(114) - 1(114) - 
SF2-9 line 1 SF2-9-3 5(137) 0.017 15(137) <0.0001 
SF2-9 line 2 SF2-9-6 5(110) 0.0272 11(110) 0.0012 
D mutated SF2-9 line 1 
D_SF2-9-2 
3(136) 0.1278 19(136) <0.0001 
D mutated SF2-9 line 2 
D_SF2-9-4 
5(155) 0.0221 17(155) <0.0001 
ABD mutated SF2-9 line 1 
AB-D_SF2-9-1 
0(140) 1 0(140) 0.4488 
CD mutated SF2-9 line 1 
C-D_SF2-9-1 
11(116) 0.0002 30(116) <0.0001 
CD mutated SF2-9 line 2 
C-D_SF2-9-3 
55(91) <0.0001 58(91) <0.0001 
DEF mutated SF2-9 line 1 
EF-D_SF2-9-4 
0(106) 1 4(106) 0.1985 
AB mutated SF2-9 line 1 
AB_SF2-9-4 
0(126) 1 0(126) 0.475 
The scoring was done in the same way as in earlier tables. 
a Compared to 40-1-4 using the Fisher’s exact test. In this study, we focused on whether the 
enhancer activity of SF2-9 is completely abolished or not. This is important for us to decide 
which motif(s) should be investigated in the future in vitro assays (such as EMSA). Some motif 
mutated SF2-9 showed significantly reduced enhancer activity, however the enhancer activity 
was not eliminated, suggesting the mutated enhancer fragment still can be bound by 
transcription factors, for example, BLMP-1, to up-regulate bed-3 expression. Therefore these 
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motifs, in this study, the motif C, D, E and F were not investigated in in vitro assays. 
 
 
Figure 3: Location and scores of putative BLMP-1 binding sites on SF2-9. The whole sequence 
of SF2-9 is indicated in the figure. The base number is relative to SF2. In the big red ellipse is 
the sequence of IR2. The six putative BLMP-1 binding motifs are highlighted in different colors, 
with their names and scores indicated below. Motifs A and B are obviously completely 
overlapped by IR2. A higher score indicates better match to known Blimp1 binding sites. 
 
BLMP-1 is required for the enhancer activity of sub-fragments of NspI 
Previously, blmp-1 mutation and blmp-1 RNAi were found to suppress the expression of 
Pbed-3:gfp significantly (Xie Zhengyang and Jason Tan Wei Han, unpublished data). This 
raised the possibility that BLMP-1 is required for the enhancer activity of the NspI sub-
fragments. To investigate this, we crossed the transgenes into a blmp-1 mutant background. The 
blmp-1(tm548) allele was used to study the role of BLMP-1 in Pbed-3::gfp expression. The 
tm548 mutation deletes parts of blmp-1 exon 3 and intron 3, and a section of the SET domain 
is lost. Therefore, tm548 is likely a null allele of the blmp-1 gene. 
We found that for fragments which contained the enhancer activity, such as F1, F2, SF2, 
SF2-5, SF2-6, SF2-7 and SF2-9 (Figure 2 and Table 8), blmp-1(tm548) significantly reduced 
their enhancer activity (Figure 4A, 4B, 4E and 4F). The only exception was SF2-4. Although 
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the enhancer activity of SF2-4 was significantly reduced by blmp-1(tm548) in vulval cells, the 
enhancer activity was slightly increased in the hypodermis in one extra-chromosomal array 
(percentage of animals with detectable GFP expression was increased from 26% in the original 
transgenic strain animals to 34% in the transgenic strain animals with blmp-1 mutation), while 
in the other extra-chromosomal array, the enhancer activity in the hypodermis was slightly 
decreased (percentage of animals with detectable GFP expression was decreased from 29% to 
24%), with statistically insignificant difference (Figure 4A and 4B). The data suggests that SF2-
4 expression is not affected by blmp-1(-) either positively or negatively, in the hypodermis. 
The result indicates that BLMP-1 is required for the enhancer activity of NspI sub-
fragments SF2, SF2-4 (only in vulval cells), SF2-5, SF2-6, SF2-7 and SF2-9 as well as F1 and 
F2 fragments, which suggests that BLMP-1 may bind to these sub-fragments in vivo to induce 
Δpes-10::gfp expression. These fragments share the common feature that they contain the IR2 
fragment which includes motifs A and B (Figure 2 and Figure 3). However blmp-1(-) seems to 
have no effect on SF2-4 enhancer activity in the hypodermis. It seems that in addition to BLMP-
1, unknown chromatin factors may drive the bed-3 expression in the hypodermis only through 
binding to a specific motif on SF2-4. Based on previous analysis, IR1 and IR4 are required for 
the enhancer activity of SF2-4 (Figure 2B), therefore the binding complex should be 
accompanied by IR1 and IR4. Furthermore, previously we described that the IR3 fragment is 
involved in all the fragments with enhancer activity in vulval and hypodermal cells, except in 
SF2-4. The enhancer activity of SF2-6 is significantly reduced by blmp-1(tm548) both in vulval 
and hypodermal cells. The only difference between SF2-4 and SF2-6 is that SF2-6 contains the 
IR3 fragment while SF2-4 does not. We speculate that under normal condition, IR3 recruits 
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repressor (s) to block the unknown chromatin factors from binding the specific motif on SF2-
4, while BLMP-1 still can bind motifs A and B normally to drive the endogenous bed-3 
expression. Hence, in blmp-1(-) animals, without IR3 in SF2-4, unknown chromatin factors can 
bind to the specific binding motif on SF2-4 and help to keep the enhancer activity of SF2-4 in 
the hypodermis. The logic can also explain that in blmp-1(-) animals, the enhancer activity of 
NspI sub-fragments with IR3 is significantly reduced in the hypodermis. 
blmp-1(-) also significantly reduced the enhancer activity of motifs C, D, E, F mutated 
SF2-9 (Figure 4C and 4D), consistent with the possibility that these motifs are not necessary 














Figure 4: BLMP-1 regulation of the enhancer activity of NspI sub-fragments. Mid-L4 stage 
worms were observed as described. The Fisher’s exact test was carried out between the strains 
with and without blmp-1(-) in each group. Black rectangles represent the original transgenic 
strains, while grey rectangles represent the transgenic strains with the blmp-1(tm548) 
background. The Y axis indicates the percentage of animals with detectable GFP in vulval cells 
or the hypodermis. 
A: Enhancer activity of sub-fragments of SF2 regulated by BLMP-1, in vulval cells. 
B: Enhancer activity of sub-fragments of SF2 regulated by BLMP-1, in hypodermal cells. 
C: Enhancer activity of motif mutated SF2-9 regulated by BLMP-1, in vulval cells. 
D: Enhancer activity of motif mutated SF2-9 regulated by BLMP-1, in hypodermal cells. 
E: Enhancer activity of F1 sub-fragment regulated by BLMP-1, in vulval cells. 
F: Enhancer activity of F1 sub-fragment regulated by BLMP-1, in hypodermal cells. 
Some transgenes such as SF2-9-6 appeared to have reduced expression in the blmp-1(-) mutant 
background, but the change is not statistically significant. We nevertheless believe blmp-1(-) 
reduces expression of these transgenes, given that independently generated lines with the same 
transgene is regulated by blmp-1. 
 
Identification of other chromatin factors involved in bed-3 expression 
Human Blimp1 contains a positive-regulatory domain (PR domain) which is a sub-class 
of the SET methyltransferase domain often located near the N-terminus of proteins. Although 
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some proteins in the PRDM family have the histone methyltransferase activity, the PR-SET 
methyltransferase domain in Blimp1 is thought to be inactive (Kouzarides 2002; Gyory et al., 
2004; Hohenauer and Moore, 2012). Blimp1 binds to specific binding sites on target genes 
using the Zinc finger DNA binding domain, while interacting with other chromatin factors, such 
as G9a, Prmt5, Prmt7 and LSD1, to function as a transcription repressor complex. The human 
Blimp1 and C. elegans BLMP-1 are 55% identical to each other and have the conserved PR-
SET domain and C2H2 Zinc finger domains (For the exact position of the domains, please refer 
to Figure 8. A PSI-BLAST was done between these two proteins using the tool on 
http://blast.ncbi.nlm.nih.gov/Blast.cgi). This suggested that that BLMP-1 in C. elegans may 
also interact with other chromatin factors to regulate the expression of the bed-3 gene. 
To explore this hypothesis and to identify possible cofactors of BLMP-1, we tested 
candidate chromatin factors selected based on the criterion that the chromatin factor should 
have an ortholog in human or other mammals which interacts with Blimp1 to form a 
transcription activator or repressor complex. The list of chromatin factors fulfilling the criterion 
and brief descriptions are listed in Table 12 (Few additional candidate factors were included as 
well). If disrupting the activity of a chromatin factor reduces the expression of Pbed-3::gfp, 
that factor may form a complex with BLMP-1 to regulate bed-3 transcription. 
For these candidate cofactors, we obtained RNAi feeding bacteria and tested the effect of 
RNAi on Pbed-3::gfp expression (smo-1, spr-5 and amx-1 were tested previously and not tested 
in this study). Among the genes tested, we found that only RNAi against prmt-5 and set-9 
obviously reduced the expression of Pbed-3::gfp in both vulval cells and the hypodermis. In 
vulval cells, besides RNAi against prmt-5 and set-9, RNAi against hda-1 and prmt-7 also 
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significantly reduced the GFP expression. In the hypodermis, besides RNAi against prmt-5 and 
set-9, RNAi against K04F10.1 and unc-37 was found to significantly reduce the GFP expression 
(Figure 5). Therefore, hda-1, K04F10.1, prmt-5, prmt-7, set-9 and unc-37 may be involved in 
regulation of bed-3 expression. However, currently it is unclear whether these proteins would 
interact with BLMP-1 to regulate bed-3 transcription. 
Next, we compared RNAi against blmp-1 and RNAi against genes listed above and found 
that in vulval cells, RNAi against hda-1 did not reduce expression of Pbed-3::gfp as much as 
RNAi against blmp-1. RNAi against prmt-5, prmt-7 and set-9 reduced expression of Pbed-
3::gfp more efficiently than RNAi against hda-1, however the efficiency was moderately lower 
than blmp-1 RNAi. In the hypodermis, none of the other RNAi treatments reduced the GFP 
expression level as effectively as blmp-1 RNAi did (Figure 5, data not shown). This result 
suggests that among these chromatin factors, BLMP-1 plays a major role in regulation of bed-
3 expression, whereas other factors may play more minor roles. 
 





Description of interaction between Blimp1 and 
cofactors in mammals 
PRMT5 prmt-5 Prmt5 is an arginine-specific histone methyltransferase. 
Blimp1 binds to Prmt5 to form a complex which mediates 
the levels of H2A/H4 R3 methylation in primordial and 
fetal germ cells (Ancelin et al., 2006; Eckert et al., 2008). 
PRMT7 prmt-7 Prmt7 is a type II methyltransferase like Prmt5. In a CoIP 
assay Prmt7 was found to interact with Blimp1 and 
functioned to di-methylate H2A and H4 in germ cell tumors 
(Eckert et al., 2008) 
HDAC1/2 hda-1 HDAC1/2 belong to the human histone deacetylase family 
and interact with Blimp1 to repress the expression of C-
myc, thus induce the B lymphocytes terminally 
differentiated to plasma cells. (Yu et al., 2000; Györy et al., 




SUMO1a smo-1 SUMO1 is a member of the SUMO (Small ubiquitin-
related modifier) protein family which functions as a post-
translational modifier. With the help of the E3 ligase 
PIAS1, SUMO1 covalently modifies Blimp1 at Lysine 816. 
This modification leads to the impaired ability of Blimp1 
binding to other proteins and impairs the plasma cell fate. 




unc-37 The groucho family is a set of transcriptional co-repressor 
proteins including the transducin-like enhancer of split 
(TLE) and Gro-related gene (Grg) proteins. They do not 
bind to DNA directly but are recruited by other chromatin 
factors to repress gene expression. hGrg, TLE1 and TLE2 
bind to Blimp1 to repress the expression of IFN-beta in B 
cells. (Jennings and Horowicz, 2008; Ren et al., 1999) 
G9a set-11 G9a is one of the histone H3 methyltransferase and 
methylate histone H3 lysine 9, which leads to gene 
silencing. G9a was reported to be recruited by Blimp1 to 
repress the expression of IFN-beta. (Gyory et al., 2004) 
LSD1 
 
spr-5a LSD1 is short for lysine specific de-methylase 1 and is a 
nuclear amine oxidase homolog. LSD1 specifically 
demethylates mono- or di-methyl groups on H3K4 which 
leads to gene silencing. LSD1 also acts as a transcriptional 
co-activator by removing a dimethyl group from H3K9. 
LSD1 was found to interact with Blimp1 to silence genes 




ATXN1 K04F10.1 Expansion of CAG repeats in ATXN1 will cause the 
dominantly inherited neurodegenerative disease 
Spinocerebellar ataxia type 1 (SCA1). ATXN1/Blimp1 
interaction was found in a large scale yeast two-hybrid 
screen. (Lim et al., 2006) 
MLL5 set-9 The human mixed lineage leukemia-5 (MLL5) is a histone 
methyltransferase, and plays important roles in 
hematopoiesis, spermatogenesis and cell cycle regulation. 
MLL5 contains a single PHD (plant homeodomain) Zinc 
finger and a normal SET domain. The activity of intrinsic 
methyltransferase of MLL5 is still debated, and MLL5 
often binds to other chromatin factors to act as a 
transcriptional regulation complex. Considering the similar 
structure and function of MLL5 and Blimp1, it is 
worthwhile to test the MLL5 ortholog set-9 regulating of 
bed-3 expression. (Emmerling et al., 2002; Sebastian et al., 
2009; Liu et al., 2010; Zhou et al., 2013) 
The human gene names and their related ortholog names in C. elegans are indicated. The human 
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gene function and literature evidence of their interaction with Blimp1 are briefly described. 
Occasionally, one human gene would be related to more than one orthologs in C. elegans, while 
more than one human gene would be related to one C. elegans ortholog. a These genes were 
tested by Jason Tan Wei Han previously.  
 
 
Figure 5: Identification of chromatin factors which may interact with BLMP-1. Percentage of 
Pbed-3::gfp animals with detectable GFP expression (the Y axis) and genes disrupted by RNAi 
(the X axis) are indicated. GFP expression of the mid-L4 stage worms was observed both in 
vulval cells (to the left of the figure) and the hypodermis (to the right of the figure). Significance 
was calculated by the Fisher’s exact test. Data of RNAi against all the genes are compared to 
L4440 RNAi and the significance symbols are noted on the close top of the rectangles. 
 
The blmp-1 mutation causes phenotypes observed in bed-3(sy705) mutants 
bed-3 mutants are reported to have cuticle shedding defect when growing from the L4 
stage to the adult stage and abnormal vulval cell division pattern in the early L4 stage (Frand et 
al., 2005, Inoue and Sternberg, 2010). In wild-type C. elegans animals, during vulval cell 
division, P5.p and P7.p cells each divides three rounds and forms seven descendent cells, with 
one granddaughter cell not dividing the third round. While in the bed-3(sy705) partial loss-of-
function mutant animals, more than one granddaughter cell of P5.p and P7.p often fail to divide 
the third round, causing less than seven descendent cells to be produced from P5.p and P7.p 
46 
 
(Inoue and Sternberg, 2010). Previously, a blmp-1 null allele tm548 and mutations in few other 
gene were found to reduce the expression of Pbed-3::gfp. We predicted that if these genes were 
involved in endogenous bed-3 expression, then phenotypes observed in bed-3(sy705) animals 
should be observed in these mutants as well. 
To test this, besides blmp-1(tm548) and blmp-1 RNAi, we prepared a set of RNAi reagents 
and mutants for genes which may be required for bed-3 expression. The mutants were lin-
53(n833), mes-2(bn11), spr-5(by134), F23D12.5(tm3121), tam-1(cc567) and lin-35(n745). The 
RNAi was used to target mes-2, spr-5, F23D12.5, tam-1, unc-37 and hda-1 (lin-53 was included, 
because when we carried out this test, we were not certain that lin-53 is required for repetitive 
transgene expression). N2 (wild-type) and L4440 RNAi (vector control) were also tested as 
negative controls. bed-3(sy705) was tested as the positive control. 
First, the cuticle shedding phenotype of young adult mutants and RNAi treated animals 
was observed under a Nomarski microscope. Among the positive control, about 20% of the 
bed-3(sy705) worms had the molting defect. Among the mutants and RNAi treated animals 
observed, only animals disrupting blmp-1 exhibited low penetrance cuticle shedding defect. 
Two in 136 blmp-1(tm548) worms had the molting defect. With blmp-1 RNAi, the percentage 
of animals exhibiting the molting defect was about 4%. Obviously, the cuticle shedding defect 
of blmp-1(tm548) is much weaker than that of bed-3(sy705) (blmp-1(-) phenotype is not 
statistically significant, more N2 or L4440 RNAi-treated N2 worms should be scored to improve 
the P-value). None of the other strains had an obvious cuticle shedding phenotype (Figure 6 and 
Table 13).  
Second, to assess the presence of the cell division defect, we counted the P5.p and P7.p 
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descendent cell number in mid-L4 stage worms after all cell divisions have stopped. We 
confirmed that the vulval cell division is affected in blmp-1(tm548), since the number of P5.p 
and P7.p descendants varied from four to seven. The vulval cell number was slightly affected 
in tam-1(cc567), F23D12.5(tm3121), mes-2(bn11), lin-35(n745) and spr-5(by134) mutants as 
well, suggesting the role of these genes in regulating the vulval cell division pattern. The result 
of RNAi experiments was consistent with mutants (Figure 7). Intriguingly, hda-1 RNAi showed 
a quite strong cell division defect (nearly 85% of the animals observed showed division defects) 
similar to defects in blmp-1 RNAi and bed-3(sy705). hda-1 RNAi does not affect the molting 
phenotype, which is consistent with the result that hda-1 RNAi only significantly reduces the 
expression of Pbed-3::gfp in vulval cells (Figure 5). For tam-1, mes-2, F23D12.5, lin-35 and 
lin-53, mutants or RNAi treated animals had significantly reduced expression of Pbed-3::gfp 
in vulval cells and the hypodermis. However, they only caused relatively weak vulval cell 
division defect without causing molting defects (Figure 7). This indicates that they may not 
regulate C. elegans molting and vulval cell division through regulating the expression of bed-
3. 
lin-35, tam-1 and lin-53 belong to the synMuv B family, and as previously described, they 
may regulate Pbed-3::gfp expression through the TAM-1/LIN-35-related mechanism which 
activates the repeated transgenes. SynMuv B genes act with synMuv A genes or with spr-1 to 
redundantly regulate the normal vulval development at the level of vulval cell induction 
(Bender et al., 2007; Schott et al., 2009). Thus lin-53, lin-35 and tam-1 mutant or RNAi 
phenotypes are probably not caused by reduced bed-3 expression. As for blmp-1, bed-3(sy705) 
is only a partial loss-of-function allele, while blmp-1(tm548) mutation causes much weaker 
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molting defect than bed-3(sy705) (Table 13). This indicates that blmp-1(tm548) may reduce, 
but cannot fully eliminate the expression of bed-3. We regard tm548 as a null allele of blmp-1 
as previously described. Therefore we conclude that BLMP-1 activates endogenous bed-3 
transcription. However, low level bed-3 expression does not require BLMP-1. 
 
Table 13: blmp-1(tm548) and blmp-1 RNAi animals have a weak molting defect phenotype. 
Strain % animals 
with unshed 
cuticle (n) 






N2 0(87) - L4440 0(89) -  
bed-3(sy705) 16(122) <0.0001 bed-3(sy705)* 26(42) <0.0001  
blmp-1(tm548) 1(136) 0.5220 blmp-1 4(102) 0.1245  
lin-53(n833) 0(84) 1.000 unc-37 0(116) 1.000  
lin-35(n745) 0(87) 1.000 hda-1 0(111) 1.000  
tam-1(cc567) 1(131) 1.000 tam-1 0(107) 1.000  
mes-2(bn11) 0(102) 1.000 mes-2 0(91) 1.000  
F23D12.5(tm3121) 0(110) 1.000 F23D12.5 0(81) 1.000  
spr-5(by134) 0(75) 1.000 spr-5 0(117) 1.000  
*As E. coli RNAi strain targeting bed-3 was not available, the bed-3(sy705) mutant was tested 
in parallel as the positive control. P-value was calculated using the Fisher’s exact test comparing 
to N2 or N2 animals treated with L4440 RNAi, respectively. The number of the assayed worms 
and the percentage of worms with unshed cuticle are indicated in the table. The single tam-





Figure 6: blmp-1(tm548) and RNAi against blmp-1 animals cause a molting defect phenotype. 
1: bed-3(sy705); 2: L4440 RNAi; 3: tam-1(cc567); 4: blmp-1 RNAi; 5: blmp-1(tm548); 6: 
F23D12.5 RNAi animals. The yellow arrows point to the unshed cuticles. Only young adults 






Figure 7: Average P5.p and P7.p descendent cell number of mutants and RNAi treated animals. 
Mid-L4 stage worms were counted. Genes tested in the study are possibly involved in 
regulating endogenous bed-3 expression. Significance was calculated by comparing the 
percentage of worms with the normal number descendent cells between the negative control 
(Top: N2, below: L4440) and the mutants or RNAi treated animals using the Fisher’s exact test. 
It was reported that cell numbers observed for P5.p and P7.p show no obvious difference in 
bed-3 mutants (Inoue and Sternberg, 2010), hence we combined the cell number data for P5.p 
and P7.p. 
A: Average P5.p and P7.p descendent cell number of mutants. One of the lin-53(n833) animals 
was counted with 8 descendent cells therefore the average cell number is a little more than 7. 
B: Average P5.p and P7.p descendent cell number of RNAi treated animals. bed-3(sy705) was 
used as the positive control since we did not get the RNAi bacteria strain against the bed-3 gene. 
 
BLMP-1 directly binds to bed-3 in vitro 
Expression and Purification of BLMP-1 DNA binding domain 
We wished to obtain purified BLMP-1 protein in order to carry out in vitro protein/DNA 
interaction assays such as the EMSA. We first tried to express in E. coli the full length or larger 
C-terminal BLMP-1 protein which contains the BLMP-1 Zinc finger DNA binding domain. 
However, using two different protein expression vectors (pGEX-KG with a GST tag, or pET-
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21a with a His tag) and multiple expression conditions, we could not get soluble fusion proteins 
(although the fusion proteins could be detected in the sonicated bacteria pellet) (data not shown). 
This may be caused by the large size of the fusion proteins and the formation of protein 
inclusion bodies (Georgious and Valax, 1996). The size of the BLMP-1 full length protein with 
a GST tag is nearly 114kDa, while the size of the larger BLMP-1 C-terminal protein with a 
GST tag is about 80kDa. Although the His tag is smaller than the GST tag, the size of the full 
length and C-terminal BLMP-1 proteins with a His tag is still about 89kDa and 55kDa, 
respectively. Hence, we decided to try to express a shorter fragment containing the critical DNA 
binding domain. 
To archive this goal, first we found that in C. elegans BLMP-1, a region approximately 
from amino acid 490 to amino acid 680 contains the Zinc finger DNA binding domain (Figure 
8B). Second, since the best human ortholog of C. elegans BLMP-1 isoform b is Blimp1 isoform 
1 (E value:4.2e-89, from http://www.wormbase.org) (Figure 8A and 8B), we did an alignment 
between the two proteins’ Zinc finger domains with the Clustal Omega alignment tool (Goujon 
et al., 2010; Sievers et al., 2011). We found that the sequences of these two Zinc finger domains 
are highly conserved (Figure 8C). Therefore, we constructed protein expression vectors with 
the BLMP-1 cDNA fragment encoding the amino acids 490-680. Although the size of the Zinc 
finger domains with the His tag is much smaller than the fragment with the GST tag (the former 
size is about 23kDa, while the latter size is a bit more than 49kDa), we only detected soluble 
GST fusion protein, the size of which was about 49kDa, as predicted (Figure 9). 
Next, we purified the GST tagged fusion protein based on the high affinity of GST for 
glutathione. The GST-tagged fusion protein can bind to Glutathione-Agarose beads with high 
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efficiency. As described in the Materials and Methods section, we successfully extracted the 
fusion protein from bacterial lysate using the beads, which was confirmed by a clean, ~49kDa 
protein band in the SDS-PAGE gel stained with Coomassie Blue (data not shown). The reduced 
glutathione was then used to elute the GST-tagged protein while preserving both the protein 
structure and function. After eluting the beads with elution buffer containing 10mM reduced 





Figure 8: Comparison of conserved functional domains between C. elegans BLMP-1 and 
human Blimp1. An alignment was done between the two proteins’ Zinc finger domains with 
the Clustal Omega alignment tool. 
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A: human Blimp1 protein isoform 1 with the PR-SET domain and Zinc finger domains, the 
length of the protein is 825AA.  
B: C. elegans BLMP-1 protein isoform b with the PR-SET domain and Zinc finger domains, 
the length of the protein is 817AA. Conserved Zinc finger domains are indicated. The red 
hollow rectangles in Figure 8A and 8B indicate the sequences aligned in Figure 8C, with Zinc 
finger domains involved. To the left is the amino terminus of the protein, while to the right is 
the carboxyl terminus (Figure 8A and 8B). Both A and B were modified from the protein 
graphics on NCBI websites (http://www.ncbi.nlm.nih.gov/protein/172072684?report=graph 
and http://www.ncbi.nlm.nih.gov/protein/392886983?report=graph). 
C: Alignment of the conserved Zinc finger domains between C. elegans BLMP-1 isoform b and 
human Blimp1 isoform 1. The short vertical red lines indicate the region used for protein 
expression (amino acids 490-680). An asterisk indicates positions which have a single, fully 
conserved residue. A colon indicates conservation between groups of strongly similar properties 
(scoring > 0.5 in the Gonnet PAM 250 matrix). A period indicates conservation between groups 
of weakly similar properties (scoring =< 0.5 in the Gonnet PAM 250 matrix) (Goujon et al., 
2010; Sievers et al., 2011). 
 
 
Figure 9: Soluble BLMP-1 conserved Zinc finger domain fusion protein was detected and 
purified in pGEX-KG vector. The gel was stained with Coomassie Blue. The small triangle 
points to the purified fusion protein bands with the expected fusion protein size (~49kDa). 
 
BLMP-1 binding to motifs A and B 
In a genome-wide ChIP-Seq study in C. elegans (Niu et al., 2011), it had been reported 
that BLMP-1 could bind to the intron 3 of the bed-3 gene. Our lab also found that blmp-1 
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mutation and RNAi against blmp-1 reduced the expression of Pbed-3::gfp (Xie Zhengyang and 
Jason Tan Wei Han, unpublished data). As described in previous sections, mutated motifs A and 
B completely abolished the enhancer activity of SF2-9 (Table 11). BLMP-1 was shown to be 
required for the enhancer activity of sub-fragments of NspI, including SF2-9 (Figure 4). 
Furthermore, blmp-1(-) causes phenotypes observed in bed-3(sy705) (Table 13, Figure 6 and 
Figure 7). These results made us speculate that although mammalian Blimp1 is usually 
considered to be as a transcriptional repressor, BLMP-1 in C. elegans could act as a 
transcription activator to up-regulate bed-3 expression by binding to specific motifs A and B in 
SF2-9. To test this hypothesis, we used an in vitro assay. EMSA is widely used in investigating 
the protein/DNA interaction in vitro (Garner and Revzin, 1981; Fried and Crothers, 1981; 
Hellman and Fried, 2007). Hence we decided to test the interaction between conserved BLMP-
1 Zinc finger domains and the motifs A and B. 
First, we generated a biotin end-labeled DNA fragment which corresponded to the first 
100bp of SF2-9 and contained intact motifs A, B, C and D. We named the fragment as the 
BLMP-1 Binding Fragment 1 (BBF1). One 45bp DNA fragment containing motifs A and B 
was designed as the wild-type competitor DNA, another 45bp DNA fragment containing 
mutated motifs A and B was designed as the negative control of the competitor DNA. The 
sequences on either side of and between motifs A and B are wild-type. After mixing with only 
the fusion protein, biotin end-labeled BBF1 and the excess competitor DNA, and running the 
EMSA, we found that in the lanes with only fusion protein and BBF1 added, a shifted band was 
clearly detected, which meant that the Zinc finger domain fusion protein could bind to BBF1 
in vitro. In the lanes where competitor DNA was added, the excess wild-type competitor DNA 
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(100x molar concentration compared to BBF1) significantly reduced the shifted band. When 
concentration of the wild-type competitor DNA was increased to 200x compared to BBF1, the 
shifted band was nearly eliminated. Oppositely, the excess mutated competitor DNA with the 
same concentration of wild-type competitor DNA did not have obvious effect on the shifted 
band (Figure 10A). This result indicates that the 45bp fragment containing motifs A and B can 
compete for the fusion protein. In other words, the 45bp fragment containing motifs A and B 
can bind the BLMP-1 Zinc finger DNA binding domain in vitro. 
Next, we designed the biotin end-labeled wild-type and mutated motifs A and B in a 
shorter 45bp fragment (motifs A and B were mutated together). In the competition lanes, we 
used different excess competitor DNA fragments such as single wild-type and mutated motif A, 
single wild-type and mutated motif B, motifs A and B fragment with only motif A or motif B 
mutated. In the lanes with only the fusion protein and the biotin end-labeled 45bp fragment 
containing motifs A and B, a shifted band was clearly detected, which indicates that the shorter 
fragment is enough for the fusion protein to bind to, and is also consistent with the fact that 
motifs C and D do not affect the enhancer activity of SF2-9 described in previous section. In 
the lanes with only the fusion protein and the biotin end-labeled shorter fragment containing 
mutated motifs A and B, no shifted band could be detected. Furthermore, the excess competitor 
DNA which only had one single motif, or had motifs A and B but one of the motifs was mutated, 
all lost the ability to compete. Only wild-type fragments containing intact motifs A and B still 
competed well (Figure 10B and 10C). These results strongly suggest that both motifs A and B 
are required for the BLMP-1 Zinc finger domain to bind to the enhancer element. One 
hypothesis is that the BLMP-1 Zinc finger domain needs to bind to the two sites simultaneously 
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to bind strongly. For example, BLMP-1 binds to one of the two sites, while the other site helps 
to stabilize the protein/DNA binding complex (for detailed information of the DNA fragments 









Figure 10: BLMP-1 Zinc finger domain binds to motifs A and B in EMSA assays.  
BELD: biotin end-labeled DNA. wt: wild-type biotin end-labeled DNA fragment containing 
intact motifs A and B; mut: biotin end-labeled DNA fragment containing mutated motifs A and 
B.  
FP: fusion protein (BLMP-1 Zinc finger DNA binding domain with a GST tag). The amount of 
the fusion protein in each lane is about 5μg. 
CD: competitor DNA. a+: competitor DNA fragment containing wild-type motif A; a-: 
competitor DNA fragment containing mutated motif A. b+: competitor DNA fragment 
containing wild-type motif B; b-: competitor DNA fragment containing mutated motif B. a+b+: 
competitor DNA fragment containing intact motifs A and B; a-b-: competitor DNA fragment 
containing mutated motifs A and B; a-b+: competitor DNA fragment containing mutated motif 
A and wild-type motif B; a+b-: competitor DNA fragment containing mutated motif B and wild-
type motif A. The molar amount of the biotin end-labeled DNA is ~20fmol. The molar amount 
of competitor DNA fragments used in most lanes is ~4pmol, except the lanes 3 and 4 in Figure 
10A. In these two lanes, ~2pmol competitor DNA fragments were added.  
The red arrows point to the shifted bands (protein/DNA complex); the small red triangles point 
to the unbound biotin end-labeled DNA. “+”: the component was added; “-”: the component 
was not added. 
A: EMSA with the fusion protein and BBF1. Biotin end-labeled wild-type BBF1 was added in 
each lane. The protein/DNA binding complex was competed by 45bp DNA fragments 
containing wild-type or mutated motifs A and B. The molar excess of competitors is indicated. 
B and C: EMSA with the fusion protein and biotin end-labeled 45bp fragments containing 







BLMP-1 is a positive regulator of bed-3 
BLMP-1 does not reduce Pbed-3::gfp expression through the TAM-1/LIN-35-related 
mechanism 
The expression of some repeated transgenes is up-regulated by a set of synMuv B family 
genes such as tam-1 and lin-35. Knocking out these genes will significantly reduce expression 
of repeated transgenes (Hsieh et al., 1999). There was a concern that BLMP-1 was affecting the 
Pbed-3::gfp expression by the same mechanism while we mistakenly thought that BLMP-1 can 
specifically induce the expression of the endogenous bed-3 gene. To exclude the possibility, in 
this study, first we demonstrated that lin-35(-) and tam-1(-) can significantly reduce the 
expression of Pbed-3::gfp, indicating that the expression of Pbed-3::gfp is also regulated by 
the TAM-1/LIN-35-related mechanism. Then we showed that blmp-1 RNAi has no effect on 
two integrated repeated transgenes, ayIs2 and ccIs4251; dpy-20, which are regulated by the 
TAM-1/LIN-35-related mechanism (Figure 1). Therefore, BLMP-1 dose not regulate the 
expression of Pbed-3::gfp through this mechanism, and BLMP-1 can regulate the expression 
of the endogenous bed-3 gene. 
 
BLMP-1 directly binds to the bed-3 enhancer element in vitro 
We localized the enhancer element from the 400bp SF2 fragment to a minimum 200bp 
SF2-9 element by in vivo enhancer assay (Table 8 and Figure 2B). We also identified putative 
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BLMP-1 binding site motifs A and B in SF2-9 which when mutated eliminated the enhancer 
activity of SF2-9 (Table 11). We did not carry out ChIP experiments. However ChIP-seq results 
by Niu et al. show that BLMP-1 binds to this region of the genome. Additionally, for NspI sub-
fragments which contain motifs A and B, blmp-1(-) suppresses their enhancer activity both in 
vulval cells and the hypodermis (except for SF2-4, for which blmp-1(-) suppresses the enhancer 
activity in vulval cells only) (Figure 4). These results suggest that BLMP-1 directly bind to the 
putative binding site motifs. We successfully expressed the soluble BLMP-1 C2H2 Zinc finger 
DNA binding domains with a GST tag (Figure 9). In EMSA assays, the fusion protein was 
confirmed to bind to oligonucleotides which contained the putative binding sites but not to 
oligonucleotides in which motifs A and B are mutated (Figure 10). This is the first time that C. 
elegans BLMP-1 was found to directly bind DNA in vitro. The experimental data also 
demonstrate that BLMP-1 functions as a transcriptional activator to directly induce the 
expression of bed-3. Blimp1 in other organisms such as humans and mice usually functions as 
a part of co-repressor complex to silence downstream gene expression. Although in sea urchins, 
Blimp1/Krox directly activates Wnt8 and other genes in a Cis-regulatory module (Davidson et 
al., 2002b; Minokawa et al., 2005; Livi and Davidson, 2006), the role of Blimp1 in vertebrates 
as a transcriptional activator had not been reported until recently. Powell et al. found that 
Blimp1 isoform A directly activates two genes foxd3 and tfap2a for early neural crest 
development in zebrafish, indicating the role of Blimp1 as a transcriptional activator (Powell 
et al., 2013). Our findings and these results suggest that Blimp1 has a conserved role in 
activating gene expression. Intriguingly, the presence of motifs A and B together is required for 
the fusion protein to bind. We hypothesize that the BLMP-1 may bind to the two sites 
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simultaneously to function normally. For example, BLMP-1 may bind to one of the two sites, 
while the other site helps to stabilize the protein/DNA binding complex. 
We also find that more than one unbound biotin end-labeled DNA bands were detected in 
some lanes. In addition, the location of the extra unbound biotin end-labeled DNA bands was 
different among different EMSA assays (Figure 10B and 10C). We speculate that this is caused 
by different conformations of the single stranded fragments which failed to anneal. Slightly 
different EMSA running conditions can theoretically have effects on how different 
conformations appear. We also detected two shifted bands in the lanes in Figure 10A, while the 
two other EMSA assays showed a single shifted band in each lane (Figure 10B and 10C). 
Partially degraded fusion protein may cause the phenotype. Besides, BBF1 has extra putative 
binding sites (motifs C and D) than motifs A and B that would lead to the formation of extra 
binding complexes due to structural and electrostatic end-effects (Hellman and Fried, 2007). 
Reducing BLMP-1 causes phenotypes observed in bed-3(sy705) mutant 
bed-3 was reported to be involved in molting regulation and the normal vulval cell division 
pattern. Here we found that by disrupting blmp-1, the animals showed a weak molting defect 
and severe vulval cell division pattern abnormality similar to, but not as strong as the phenotype 
observed in bed-3(sy705) (Table 13, Figure 6 and Figure 7). Considering that bed-3(sy705) is a 
partial loss-of-function allele, the result suggests that BLMP-1 is not fully responsible for 
regulation of bed-3 expression, especially in the hypodermis. Additional transcription factors 
likely also regulate the expression of bed-3. Actually, in studying the effect of blmp-1(-) on 
enhancer activity of NspI sub-fragments, we found that the enhancer activity of a sub-fragment 
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named SF2-4 which does not contain the IR3 element in the hypodermis was only slightly 
affected by the blmp-1 mutation, suggesting a redundant regulatory role of BLMP-1 on SF2-4 
enhancer activity in the hypodermis, with the existence of other regulators. Although human 
Blimp1 is generally treated as a master regulator for B lymphocytes differentiation, myc is 
reported to be repressed by Blimp1 both directly and indirectly through repression of an 
important activator E2F (Shaffer et al., 2002; Martins and Calame, 2008). Thus, it is common 
for Blimp1 target genes to be regulated by multiple mechanisms, as bed-3 is by blmp-1. 
 
Other chromatin factors possibly involved in bed-3 transcription regulation are 
identified 
In human and other organisms such as mice and zebrafish, Blimp1 is usually found to 
recruit other chromatin factors to form a transcriptional activator or repressor complex. Here 
we chose a set of Blimp1 cofactor orthologs in C. elegans and used RNAi to test their function 
in bed-3 regulation (Table 12). Some chromatin factors, such as PRMT-5, the ortholog of Prmt5, 
an arginine-specific histone methyltransferase, and SET-11, the ortholog of G9a, a histone H3 
methyltransferase related to gene silencing, were identified to be possibly involved in bed-3 
regulation since RNAi against them reduced the expression of Pbed-3::gfp. HDA-1 is the 
ortholog of human histone deacetylase family member HDAC1/2. Knocking down hda-1 
reduced the expression of Pbed-3::gfp in vulval cells and severely disrupts the vulval cell 
division pattern (Figure 5 and Figure 7B). hda-1 is also a member of the synMuv B family and 
negatively regulate vulval cell division as other members in this family do (Cui et al., 2006; 
Cui and Han, 2007). However, recently it was reported that hda-1 is required for normal vulval 
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morphogenesis, and cell fate differentiation in the terminal division round of P5.p, P6.p and 
P7.p, and hda-1 has a similar expression pattern compared to bed-3 (Ranawade et al., 2013). 
These findings suggest that hda-1 has a role in regulating bed-3 expression. Considering that 
HDACs often play a role in gene inactivation, HDA-1 may up-regulate bed-3 expression in an 
indirect way by repressing bed-3 repressors. 
 
Altogether, in this study, we successfully localized the enhancer element on intron 3 to a 
minimum SF2-9 200bp region. We also identified the exact BLMP-1 binding sites on SF2-9, 
and the binding sites were confirmed by EMSA assay with BLMP-1 Zinc-finger DNA binding 
domain. Additionally, we observed the molting defect and vulval cell division pattern disruption 
in blmp-1 mutants. Some chromatin factors were also identified to possibly regulate 
endogenous bed-3. Therefore, BLMP-1 is a positive regulator for bed-3 transcription. The result 
can help us further understand the gene regulatory network regulating bed-3 and explore the 
mechanisms of molting and vulval cell division regulation. Given the conserved functional 
domains of Blimp1, our study also potentially provide a clue to the transcriptional regulation 
by Blimp1 among different organisms, especially the role of Blimp1 as an evolutionary 
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